Ulcerative colitis triggered by pegylated interferon alpha-2b in a patient with chronic hepatitis B: A case report and literature review
| Autor: | Ze-Qian Wu, Dong-Ying Xie, Jian Tang, Peipei Wang, Dabiao Chen, Zhishuo Mo |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Exacerbation Side effect Colonoscopy RC799-869 Gastroenterology Hepatitis 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Mesalazine Pegylated interferon Interferon Chronic hepatitis C (CHC) Internal medicine medicine Chronic hepatitis B (CHB) Ulcerative colitis (UC) Hepatology medicine.diagnostic_test business.industry Interferon (IFN) Diseases of the digestive system. Gastroenterology medicine.disease Ulcerative colitis 030104 developmental biology chemistry 030211 gastroenterology & hepatology Histopathology business medicine.drug |
| Zdroj: | Liver Research, Vol 5, Iss 2, Pp 97-101 (2021) |
| ISSN: | 2542-5684 |
| DOI: | 10.1016/j.livres.2021.04.001 |
| Popis: | Interferon (IFN) is a multifaceted immunomodulator that is effective against many diseases, including chronic hepatitis B and chronic hepatitis C infection. IFN defends against viral infection, but may also cause various side effects, such as ulcerative colitis (UC). Herein, we present a case of UC triggered by pegylated interferon alpha-2b (PEG-IFN-α-2b) therapy in a patient with concurrent chronic hepatitis B (CHB) infection. The diagnosis was based on typical clinical symptoms, colonoscopy findings, colonic mucosal biopsy, and histopathology. Accordingly, treatment with mesalazine was initiated without stopping PEG-IFN-α-2b. Fortunately, UC relieved gradually without compromising the effects of treatment. Simultaneously, we conducted a literature review of previously published case reports on the side effect of UC in patients with underlying chronic hepatitis. Various reactions have been reported, including induction, exacerbation, and no change. This is the first report of UC triggered by PEG-IFN-α-2b in a CHB patient. We recommend that physicians pay attention to the rare side effect of UC during administration of PEG-IFN-α-2b. Mesalazine can relieve UC with sustained use of PEG-IFN-α-2b. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|